candesartan has been researched along with sirolimus in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Daida, H; Dohi, T; Iesaki, T; Kasai, T; Kubota, N; Miyauchi, K; Ogita, M; Tsuboi, S; Tsuruta, R; Yokoyama, T | 1 |
| Kikuta, K; Kimura, K; Koide, S; Matsui, K; Matsumura, T; Nakao, K; Ogawa, H; Oka, H; Oshima, S; Sakamoto, T; Shimomura, H; Yamamoto, N | 1 |
| Chen, JW; Jiang, Y; Liu, D; Murao, K; Sun, WP; Wang, LH; Xue, R; Zhang, GX | 1 |
1 review(s) available for candesartan and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for candesartan and sirolimus
| Article | Year |
|---|---|
Rationale, design and baseline characteristics of a study to evaluate effects of candesartan on cardiovascular events after drug-eluting stent implantation in patients with ischemic heart disease.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Clinical Protocols; Combined Modality Therapy; Drug Discovery; Drug-Eluting Stents; Female; Humans; Japan; Male; Middle Aged; Myocardial Ischemia; Paclitaxel; Sirolimus; Tetrazoles | 2013 |
3 other study(ies) available for candesartan and sirolimus
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Candesartan with pioglitazone protects against endothelial dysfunction and inflammatory responses in porcine coronary arteries implanted with sirolimus-eluting stents.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Coronary Vessels; Drug Therapy, Combination; Drug-Eluting Stents; Endothelium, Vascular; Hypoglycemic Agents; Inflammation; Pioglitazone; Protective Agents; Sirolimus; Sus scrofa; Tetrazoles; Thiazolidinediones; Treatment Outcome | 2011 |
Autophagy contributes to angiotensin II induced dysfunction of HUVECs.
Topics: Acetophenones; Adenine; Angiotensin II; Animals; Autophagosomes; Autophagy; Autophagy-Related Proteins; Benzimidazoles; Biphenyl Compounds; Decanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxy Acids; Models, Biological; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphorylation; Signal Transduction; Sirolimus; Tetrazoles; Time Factors | 2021 |